tradingkey.logo
tradingkey.logo
Suchen

Twist Bioscience Corp

TWST
Zur Watchlist hinzufügen
49.170USD
-3.780-7.14%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
3.06BMarktkapitalisierung
VerlustKGV TTM

Twist Bioscience Corp

49.170
-3.780-7.14%

mehr Informationen über Twist Bioscience Corp Unternehmen

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corp Informationen

BörsenkürzelTWST
Name des UnternehmensTwist Bioscience Corp
IPO-datumOct 31, 2018
CEOLeproust (Emily M)
Anzahl der mitarbeiter979
WertpapierartOrdinary Share
GeschäftsjahresendeOct 31
Addresse681 Gateway Blvd.
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon18007190671
Websitehttps://www.twistbioscience.com/
BörsenkürzelTWST
IPO-datumOct 31, 2018
CEOLeproust (Emily M)

Führungskräfte von Twist Bioscience Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
398.19K
-1.29%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
69.20K
-4.11%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
52.14K
-3.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
26.07K
-4.28%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
20.75K
-7.23%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
13.28K
+21.80%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
13.14K
-73.06%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
398.19K
-1.29%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
69.20K
-4.11%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
52.14K
-3.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
26.07K
-4.28%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NGS applications
52.64M
50.76%
DNA synthesis and protein solutions
51.06M
49.24%
Nach RegionUSD
Name
Umsatz
Anteil
Americas
58.38M
56.30%
EMEA
38.37M
37.00%
APAC
6.95M
6.70%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NGS applications
52.64M
50.76%
DNA synthesis and protein solutions
51.06M
49.24%

Aktionärsstatistik

Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Artisan Partners Limited Partnership
10.23%
ARK Investment Management LLC
10.19%
EdgePoint Investment Group Inc.
8.64%
William Blair Investment Management, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.71%
Andere
54.78%
Aktionäre
Aktionäre
Anteil
Artisan Partners Limited Partnership
10.23%
ARK Investment Management LLC
10.19%
EdgePoint Investment Group Inc.
8.64%
William Blair Investment Management, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.71%
Andere
54.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
64.84%
Investment Advisor/Hedge Fund
35.76%
Hedge Fund
8.42%
Research Firm
5.50%
Pension Fund
1.72%
Individual Investor
1.41%
Bank and Trust
0.59%
Family Office
0.16%
Insurance Company
0.03%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
592
78.48M
126.03%
-339.29K
2025Q4
585
73.72M
120.24%
-3.30M
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Artisan Partners Limited Partnership
6.22M
10.14%
+387.01K
+6.64%
Feb 27, 2026
ARK Investment Management LLC
7.56M
12.33%
+832.69K
+12.38%
Dec 31, 2025
EdgePoint Investment Group Inc.
5.38M
8.77%
+1.30M
+31.74%
Dec 31, 2025
William Blair Investment Management, LLC
5.95M
9.71%
+1.81M
+43.75%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.80M
7.83%
-12.17K
-0.25%
Dec 31, 2025
State Street Investment Management (US)
3.63M
5.92%
+538.75K
+17.44%
Dec 31, 2025
Soleus Capital Management, L.P.
1.86M
3.04%
-4.43K
-0.24%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.50M
2.45%
+189.78K
+14.49%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil6.24%
iShares Genomics Immunology and Healthcare ETF
Anteil3.92%
Global X Genomics & Biotechnology ETF
Anteil2.09%
ROBO Global Healthcare Technology & Innovation ETF
Anteil2%
WisdomTree BioRevolution Fund
Anteil1.79%
ARK Innovation ETF
Anteil1.47%
Franklin Genomic Advancements ETF
Anteil1.17%
State Street SPDR S&P Biotech ETF
Anteil0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.66%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.56%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI